Aileron and Scripps Ink Deal

Xconomy Boston — 

Cambridge, MA-based Aileron Therapeutics, a  developer of peptide-based drugs, said today it gained exclusive rights to “click” chemistry from The Scripps Research Institute in La Jolla, CA. “Click chemistry describes synthetic chemistry tailored to generate substances quickly and reliably by joining (“clicking”) small reactive molecular building blocks together selectively and covalently to drive a spontaneous and irreversible binding reaction, a process that is inspired by natural chemistry,” the company and Scripps said in a press release. The press release did not provide financial details of the agreement. The Nobel laureate K. Barry Sharpless, a chemistry professor at Scripps Research, developed the technology involved in this agreement.